Professor Nicholas Buckley is a leading academic in Clinical Pharmacology at the University of Sydney and holds a Visiting Professor position at the University of Peradeniya, Sri Lanka. He serves as Research Director for the South Asian Clinical Toxicology Research Collaboration (SACTRC) and is a Consultant Clinical Pharmacologist & Toxicologist at the NSW Poisons Information Centre and Royal Prince Alfred Hospital. His work focuses on improving clinical toxicology practices, poison control policies, and understanding mechanisms of drug toxicity. Co-founder of SACTRC for agrochemical poisoning and snakebite research Chair of Australian Therapeutic Guidelines - Toxicology writing group Editorial roles in Clinical Toxicology, Drug Safety, and Australian Prescriber Research Interests include toxicovigilance, epidemiology of poisoning, acute kidney injury in poisoning/snakebite, pesticide safety interventions, antidote development, and pharmacoepidemiology of psychotropic drugs. His work combines clinical trials, population surveillance, and translational research. Scientific Contributions span 440+ peer-reviewed articles and 22 book chapters, with continuous funding since 2002. He has supervised over 20 higher degree students and leads international collaborations in low-and-middle-income countries through NIHR RIGHT4. Key Affiliations : Member of Charles Perkins Centre, Australian Medicines Handbook Editorial Advisory Board, and NIHR RIGHT4 programme.
Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.
Associate Professor Gilda Carvalho is a leading researcher at the Australian Centre for Water and Environmental Biotechnology (ACWEB) and the School of Chemical Engineering at the University of Queensland. She leads the Drinking and Recycled Water research group and specializes in Environmental Bioengineering , focusing on microbial processes for water/wastewater treatment and resource recovery. Research areas: Chemicals of Emerging Concern (CEC), Biological Nutrient Removal (BNR), biofilm systems, membrane processes, and polyhydroxyalkanoate (PHA) production Key methodologies: Molecular tools linking microbial ecology to process performance Academic output: Over 90 peer-reviewed papers and >40 multinational research projects with industrial partners Educational impact: Coordinator of Postgraduate Programs in Urban Water Engineering and supervisor of >20 PhD students Her recent research explores phage-based biofilm disruption , micropollutant removal via advanced oxidation, and resource recovery from waste streams. Current funding includes projects on biofilm solutions for drinking water and sustainable wastewater reuse. She integrates multidisciplinary approaches across biotechnology, chemical engineering, and environmental science to address global water challenges.
David Caldicott is a Clinical Associate Professor at the Australian National University (ANU) School of Medicine and Psychology , where he contributes to interdisciplinary research and education. He also serves as an Emergency Medicine Consultant Physician at North Canberra Public Hospital, integrating clinical practice with academic work. Education: B.Sc.(Hons) MBBS (London) FRCEM (Fellow of the Royal College of Emergency Medicine) Dip.Med.Tox (Diploma in Medical Toxicology) Research Interests: Dr. Caldicott specializes in emergency medicine and clinical toxicology, with a focus on illicit and novel psychotropic substances , medical cannabis , and toxicological crises . His work bridges clinical practice and public health, particularly in mass gathering medicine , disaster medicine , and medical responses to terrorism . He also explores the intersection of music festivals and emergency medical planning. Contact & Location: He can be reached at david.caldicott@act.gov.au or by phone at +61 2 6201 6111. His clinical work is based at the Emergency Department, North Canberra Hospital, 5 Mary Potter Circuit, Bruce ACT 2617.
Dr. Holger Scheib is an Honorary Associate Professor in the School of the Environment at The University of Queensland. His research focuses on venom evolution, toxinology, and biomedical applications, particularly in reptiles, cnidarians, and other venomous organisms. He collaborates extensively with international researchers on projects involving venom structure-function relationships, evolutionary biology, and clinical implications of venom variation. Research interests span venom evolution, toxin structure and function, and their applications in biomedical contexts. He investigates venom diversity across species, including reptiles, sea anemones, and cnidarians, focusing on how these toxins interact with biological systems. His work also explores the intersection of venom components with allergens and their structural similarities, contributing to a deeper understanding of venom’s ecological and medical significance. His recent publications highlight advancements in understanding venom evolution, toxin structures, and clinical implications. Studies include comparisons of venom proteins with allergens, analyses of venom variation in rattlesnakes, and investigations into the molecular mechanisms of bacterial secretion systems. These works contribute to both basic biological research and potential applications in medicine and biodiscovery. No scientific awards or grants are explicitly mentioned in the provided text. Dr. Scheib’s research is primarily conducted through collaborations within the School of the Environment and international academic networks. No specific lab or team affiliations are detailed.
Dr. Yi David Ju is a Senior Research Fellow at RMIT University's School of Science and an ARC DECRA Fellow at La Trobe University's School of Cancer Medicine. He leads the Nanomedicine and Gene Therapeutics Laboratory at the Olivia Newton-John Cancer Research Institute (ONJCRI) and holds Honorary Fellowships at the University of Melbourne's Department of Microbiology & Immunology and Chemical Engineering. PhD from University of Melbourne (2017, Frank Caruso) 2017–2021 : Research Fellow at University of Melbourne 2021 : Vice-Chancellor’s Postdoctoral Fellow at RMIT 2023 : Visiting Researcher at University of Manchester's Nanomedicine Lab His research focuses on Bio-Nano Interactions , particularly Nanoparticle-Immune System dynamics, Lipid Nanoparticle Engineering for mRNA Delivery , and Poly(ethylene glycol) Alternatives . Key contributions include stealth nanoparticles for prolonged circulation, anti-PEG antibody dynamics in vaccine development, and patient-specific targeting models for chronic lymphocytic leukemia . Recent publications analyze hybrid immuno-PET-MRI probes for inflammation monitoring, zwitterionic PEG nanoparticles for reduced immunogenicity, and RAFT polymer-based LNPs for enhanced gene delivery . His work also explores supramolecular DNA-polyphenol assemblies and metal-phenolic coatings for controlled drug release . Scientific Awards ： 2023 ACIS ECR Lectureship Finalist, 2023 ACS Nano Impact Award 2022&2023 RMIT Enabling Capability Platform Funding 2021 CBNS Most Significant Publication Award 2020 CBNS Career Development Award 2019 Outstanding Postdoctoral Researcher Award 2019 Nanoscale Advances Oral Prize 2017 Reviewer Excellence Award for Chemistry of Materials 2014 Best Tutor Award Professional Roles ： Associate Editor, Journal of Materials Science Committee Member, Royal Australian Chemical Institute (Victorian Branch) Active Member, Australasian Colloid and Interface Society
Rachel Huxley is Deakin Distinguished Professor and Executive Dean of the Faculty of Health at Deakin University, a role she has held since October 2019. She leads the Faculty of Health and is based at the Melbourne Burwood Campus. She previously served as Associate Pro-Vice Chancellor (Research) at La Trobe University, Chair in Epidemiology at the University of Queensland, and Head of the School of Public Health at Curtin University. She holds honorary appointments at the George Institute for Global Health (UNSW) and the Nuffield Department of Population Health, University of Oxford. Education: Undergraduate studies at St John's College, Oxford Doctorate in Epidemiology and Public Health, Department of Public Health and Primary Care, Oxford University Post-doctoral training at Oxford University Professor Huxley's research centers on epidemiology and public health, with a focus on chronic disease risk factors, sex and ethnic disparities, and the health impacts of climate change and air pollution. Her work spans cardiovascular disease, obesity, diabetes, women's health, and environmental determinants of health. She has published over 200 research articles and maintains an h-index of 58 (Web of Science). The 15 most recent publications reflect a strong interdisciplinary focus on environmental health, mental health, cardiometabolic disease, and health policy. Key themes include air pollution and child obesity, climate change and asthma, green space and psychiatric disorders, and sex disparities in coronary heart disease care. Her research increasingly integrates planetary health, policy reform, and equity considerations. Scientific Awards and Fellowships: Inaugural Career Development Fellowship from the Heart Foundation and NSW Office for Science and Medical Research Career Development Award ($400K) from NSW and National Heart Foundation of Australia (2009–2010) Professor Huxley has secured over $2.5 million as Chief Investigator A and contributed to more than $5 million in co-investigator grants. Current and recent projects include NHMRC-funded studies on obesity, prediabetes, electronic cigarettes, women's health data, CT scanning risks, and coronary heart disease management. She supervises several doctoral students and is actively involved in national and international advisory boards, including the Telethon Kids Institute and the Australian Clinical Trials Alliance. She leads or contributes to major research initiatives such as the Centre of Research Excellence on Women and Non-communicable Disease (CRE WaND) and the Breathe Melbourne citizen science project. Her leadership extends to policy engagement, with research influencing public health strategies on air quality, climate change, and sex and gender equity in research.
Dr. Maryam Roudbary is an Adjunct Senior Lecturer at the Westmead Clinical School, part of the Sydney Medical School, University of Sydney. She joined the Sydney Infectious Diseases Institute (Sydney ID) in 2023 as a researcher affiliated with the University of Sydney and employed by NSW Health and Research Network as a Senior Researcher in Mycology. Previously, she served as an Associate Professor at Iran University of Medical Sciences (2015–2022), leading research projects and supervising Master’s and PhD students in medical mycology and fungal infections. Her PhD in Medical Mycology focused on antifungal resistance mechanisms and new therapeutic strategies. Current research priorities include developing novel antifungal agents against drug-resistant fungi, understanding resistance mechanisms, and addressing challenges outlined in the WHO’s 2022 Fungal Priority Pathogen List. She is an editor for several mycology journals and co-authored The Book of Fungal Pathogens (2022). Roudbary’s work spans epidemiological studies, clinical sampling, and collaborations in One Health AMR initiatives. She leads projects on fungal diversity exploration (e.g., Vietnam citizen science initiatives) and evaluates natural compounds (e.g., thymus extracts, nanoparticles) for antifungal efficacy. Recent grants include a 2025 project on antifungal peptide-based therapeutics. Her research emphasizes biofilm formation in filamentous fungi, Candida species pathogenesis, and fungal co-infections in immunocompromised patients, including those with severe COVID-19. Key findings include the prevalence of azole-resistant Candida species in Iran and the role of gene expression (e.g., CDR1 , HWP1 ) in drug resistance. Roudbary’s contributions include over 100 peer-reviewed articles, grants focusing on antifungal innovation, and active roles in international mycology networks. She bridges clinical and research domains through translational studies targeting critical fungal health challenges.
Professor Shanlin Fu is a distinguished academic at the University of Technology Sydney (UTS), holding the position of Professor in the School of Mathematical and Physical Sciences and affiliated with the Centre for Forensic Science. He serves as the Program Director for the Bachelor of Forensic Science program and is a Research Integrity Adviser for the Faculty of Science. With over $10 million in competitive research funding from ARC, NHMRC, and other national and international schemes since 2008, Professor Fu leads the Drugs and Toxicology Group, focusing on developing sensitive methods for clinical diagnosis, therapeutic drug monitoring, and drugs of abuse testing. Professor, UTS School of Mathematical and Physical Sciences (2019-present) Associate Professor, UTS School of Chemistry and Forensic Science (2015-2019) Senior Lecturer, UTS School of Chemistry and Forensic Science (2008-2014) Professor Fu earned his PhD in Medicinal and Pharmaceutical Chemistry from the University of Sydney (1989-1992), an MSc in Phytochemistry from Peking Union Medical College (1982-1985), and a BSc in Biology from Nanjing Normal University (1978-1982). Prior to his academic career at UTS, he served as a Senior Hospital Scientist at the Northern Sydney Area Health Service (2000-2008) and as a Senior Research Scientist at The Heart Research Institute (1993-2000). Professor Fu's research spans analytical chemistry, forensic chemistry, medical biochemistry, pharmacology, pharmaceutical sciences, forensic toxicology, and clinical toxicology. His work focuses on three main areas: Forensic Chemistry concerning identification of drugs of abuse including new psychoactive substances; Forensic Toxicology focusing on detection of drugs in biological matrices for clinical and medico-legal purposes; and Clinical Toxicology aiming to understand mechanisms of substance abuse harms. His research has strong real-world applications, with his patented 'Cathinone Test' already commercialized for law enforcement and potential healthcare settings. Analysis of Professor Fu's recent publications reveals a strong emphasis on developing innovative analytical methods for drug detection, particularly for new psychoactive substances. His work increasingly incorporates multi-omics approaches (metabolomics, lipidomics, proteomics) and machine learning techniques to enhance detection capabilities. There's a clear trend toward translating laboratory research into practical field applications, with numerous color spot tests and portable detection methods being developed for law enforcement use. His research also shows expanding applications in equine doping control and postmortem analysis. Vice-Chancellor's Medal for Research Excellence through Collaboration or Partnership (2023) UTS Teaching and Learning Award for Team Teaching (2022) MAPS Research Translation Award (2022) As a member of the HDR Panel since 2022, Professor Fu actively supervises Masters Research and PhD students in forensic science. His extensive grant portfolio includes leadership of the ARC Research Hub for Integrated Device for End-user Analysis at Low-levels and the Australian Centre for cannabinoid clinical and research excellence (ACRE). He has established key collaborations with Australian Federal Police, NSW Forensic and Analytical Science Service, Racing NSW, and international institutions including University of Copenhagen and University of Dundee. His research impact extends beyond academia through commercialization of detection technologies that improve efficiency and accuracy of illicit drug detection. Professor Fu heads the Drugs and Toxicology Group at the Centre for Forensic Science, which maintains strong industry partnerships with forensic laboratories and law enforcement agencies. His group is currently developing a multiplexer device that can simultaneously detect multiple new psychoactive substances including cathinones, NBOMEs, piperazines, and fentanyl analogues. The group's work bridges fundamental research with practical applications, with several technologies moving from the laboratory to real-world implementation in forensic and healthcare settings.
Professor Loc Do is a dentist and oral epidemiologist specializing in social and clinical oral epidemiology. He holds a PhD from the University of Adelaide and currently serves as Director of Research at the School of Dentistry, University of Queensland. His research focuses on child and adult oral health disparities, fluoride efficacy, and water fluoridation policies. He has led major studies like the National Child Oral Health Study (2012–14) and the National Study of Adult Oral Health (2017–19). Education: BDS (Dentistry), MScDent, PhD (Oral Epidemiology). Research Interests: Oral epidemiology, dental fluorosis, socioeconomic inequalities in oral health, fluoride risk-benefit analysis, and complex systems science in dental research. His work frequently addresses public health interventions and policy implications. Awards: 2022 IADR Distinguished Scientist H Trendley Dean Award, 2023 IADR Abrey Sheiham Award for Distinguished Research in Dental Public Health. Grants and Projects: Principal Investigator for NHMRC/MRFF-funded studies on water fluoridation, child oral health inequities, and aged care oral health. Current projects include the Queensland Child Oral Health Study (2020–2024) and the SMILE Birth Cohort Study (2013–22). Advisement: Supervises PhD and Master’s students in areas like oral health policy, fluoride safety, and aged care interventions. Notable supervision includes studies on water fluoridation’s social impact and oral health in residential care facilities. Labs/Teams: Leads research teams in the School of Dentistry and collaborates with the Centre of Research Excellence on Achieving the Tobacco Endgame. Active in multidisciplinary projects addressing global oral health challenges.
Dr. Ong Yong Sze is a Lecturer at Monash University Malaysia’s School of Pharmacy, specializing in precision oncology and nanomedicine. She holds a PhD in Pharmacology (2019) and a Bachelor of Biomedical Science (2013), both from Universiti Putra Malaysia. Her research focuses on cancer nanomedicine, natural product-based therapeutics, and environmental health risk assessment, with a commitment to developing low-toxicity therapies and addressing environmental pollutants’ health impacts. She has received prestigious awards, including the PeerJ Award for Best Poster (2021) and Oral Presentation Award (2025). Education: PhD in Pharmacology, Universiti Putra Malaysia (2019) Bachelor of Biomedical Science, Universiti Putra Malaysia (2013) Research Interests: Her work bridges nanotechnology, natural pharmacology, and toxicity studies. Key areas include engineering targeted nanoparticle drug delivery systems, exploring plant-derived anticancer compounds, and evaluating environmental pollutants like microplastics. Her interdisciplinary approach aims to enhance therapy precision while ensuring patient safety. Grants & Projects: She leads and collaborates on projects such as Development of a 3D Metastatic Breast Cancer-on-Chip Model (2023–2025) and Engkabang as High-Quality Cosmeceuticals (2023–2026), focusing on drug delivery, gut health, and functional foods. Lab & Teams: Her lab integrates nanomedicine and environmental toxicology, with collaborations spanning Malaysia, Portugal, and Taiwan. She actively organizes workshops on cell culture and drug discovery, furthering academic engagement.
Pilar Blancafort is an Associate Professor at The University of Western Australia (UWA), holding positions in the School of Human Sciences and UWA Medical School. She is affiliated with the UWA Centre for Medical Research and collaborates with the Harry Perkins Institute of Medical Research. Her research focuses on epigenetic manipulation in cancer models, particularly breast and ovarian cancers, leveraging CRISPR/Cas9 and genome engineering technologies to develop precision medicine tools. She has co-led projects such as the Lionheart FX Automated High-Content Microscope initiative and actively investigates therapeutic reprogramming of cellular signaling pathways to improve cancer treatment outcomes. Blancafort’s research expertise includes genome engineering, cancer epigenetics, and women’s cancers. She collaborates internationally and has contributed to over 70 publications, 14 datasets, and 43 grants. Her work aligns with UN Sustainable Development Goals, emphasizing global health and innovation in medical research. Key areas of exploration involve reactivating tumor suppressors, silencing oncogenic drivers, and enhancing immune responses through CRISPR-based systems. Her studies on the PI3K-AKT-mTOR pathway and novel oncogenes further underscore her commitment to advancing targeted therapies. Blancafort has supervised 11 students and leads multiple grants, including projects on metastatic breast cancer therapies and ovarian cancer reprogramming. Her lab at the UWA Centre for Medical Research explores translational strategies for epigenome editing in cancer, with a focus on clinical applicability. Recent work highlights lipid nanoparticle delivery systems for CRISPR/dCas9 and synthetic epigenetic approaches to reverse mesenchymal-epithelial transitions in breast cancer.
Lionel Hebbard is a Professor in the Department of Molecular and Cellular Biology at James Cook University's College of Medicine and Dentistry. His research spans hepatocellular carcinoma mechanisms, metabolic liver disease, and cancer therapeutics with significant contributions to adiponectin biology and sarcopenia assessment in cardiac surgery. James Cook University (Current) Department of Molecular and Cellular Biology College of Medicine and Dentistry Senior Researcher in Liver Cancer Biology His research focuses on hepatocellular carcinoma pathogenesis , particularly adiponectin signaling pathways and liver cancer stem cells. He investigates non-alcoholic fatty liver disease progression to cancer, metabolic drivers of tumorigenesis, and therapeutic targeting using aptamer-based delivery systems. Recent work explores sarcopenia quantification via CT imaging for cardiac surgery risk prediction, demonstrating clinical translation of his molecular findings. His lab employs advanced techniques including CRISPR screening (TARGET-SL platform), in vitro cancer models, and murine tumor systems. Analysis of his 15 most recent publications reveals strong emphasis on translational liver cancer research (60%), cardiac surgery complications (20%), and emerging biotechnologies (20%). Key trends include adiponectin's dual roles in fibrosis and tumorigenesis, sarcopenia as a surgical biomarker, and aptamer-based targeting of cancer stem cells. His work consistently bridges molecular mechanisms with clinical applications, particularly in hepatocellular carcinoma diagnostics and treatment. He mentors multiple doctoral students and early-career researchers including Rhys Gillman and Miriam Wankell. His research is supported by continuous funding from Australian NHMRC and international collaborations with George Jacob (Westmead Institute), Qiao Liang (Bentham Books), and Ranscht Barbara (T-cadherin studies). He leads the Hepatic Cancer Biology laboratory focusing on: Liver cancer stem cell characterization Adiponectin receptor signaling in HCC Metabolic drivers of tumor progression Novel drug delivery systems for liver cancer Translational sarcopenia assessment tools
Dorrit Jacob is a Professor and Director of the Research School of Earth Sciences at the Australian National University (ANU), within the College of Science. She holds a Dr. rer. nat. from Georg-August University in Göttingen, with her master's and PhD research conducted at the Max-Planck Institute for Chemistry in Mainz. Recognized nationally, she was awarded the DFG Heisenberg Chair in Biomineralisation in 2012, becoming the first female recipient of this honor in Rhineland-Palatinate and at Johannes Gutenberg University Mainz. In 2013, she relocated to Australia, taking up an ARC Future Fellowship at Macquarie University before being promoted to full Professor in 2016. Since November 2020, she has served as the first female School Director of the Research School of Earth Sciences. Her research focuses on biomineralization, diamond formation, Earth's mantle geochemistry, and advanced analytical techniques like laser ablation ICP-MS and vibrational spectroscopy. She leads interdisciplinary projects, including collaborations on carbon sequestration, material science, and environmental applications. Notable awards include the DFG Heisenberg Professorship and contributions to understanding mantle dynamics through diamond inclusions and mantle xenolith studies. Dr. Jacob's work spans geology, geochemistry, and biomineralization, with over 150 publications. Her research teams investigate topics like nacre growth mechanisms, sulfide-rich continental roots, and deep carbon cycles. She supervises students in these areas and collaborates on grants related to microanalysis, climate proxies, and mantle processes. Her labs and teams at ANU and international institutions advance understanding of Earth's materials and environmental systems.
Michelle Tate is an Adjunct Associate Professor (Research) at the Hudson Institute of Medical Research, where she leads the Viral Immunity and Immunopathology research group and serves as Deputy Centre Head at the Centre for Innate Immunity and Infectious Disease. She earned her PhD in Microbiology and Immunology from the University of Melbourne in 2010 and has since established herself as a leading researcher in viral immunology and pathogenesis. Institution: Hudson Institute of Medical Research School: Centre for Innate Immunity and Infectious Disease Academic Rank: Adjunct Associate Professor Email: michelle.tate@hudson.org.au Education: PhD in Microbiology and Immunology, University of Melbourne (2010) Dr. Tate's research centers on the molecular mechanisms driving hyperinflammation and severe disease during viral infections, particularly influenza A virus. Her work investigates how the host immune response—specifically inflammasome signaling, pyroptosis, and interferon pathways—contributes to immunopathology. She aims to develop host-directed therapies that modulate inflammation to reduce lung damage and improve outcomes in respiratory viral diseases. Her research integrates animal models, molecular immunology, and translational approaches to bridge basic science with clinical applications. Analysis of her recent publications reveals a strong focus on inflammasome biology (especially NLRP3 and gasdermin-mediated pyroptosis), host-pathogen interactions in influenza, and immune protection in non-traditional sites such as the male reproductive tract. Her work spans immunology, virology, pulmonary disease, and therapeutic development, with an emphasis on targeting innate immune pathways for treatment. Australian Institute of Policy and Science (AIPS) Young Tall Poppy Science Award (2018) Christina Fleischmann Memorial Award (2016) Victorian Infection and Immunity Network Career Development Award (2016) Commendation, Victorian Premier’s Award for Health & Medical Research (2011) Chancellor's and Dean's Prize for PhD Excellence (2011) Bridging Postdoctoral Fellowship (2011) Dr. Tate actively contributes to the scientific community through NHMRC and MRFF grant review panels, editorial roles in journals such as Journal of Virology and Pathogens, and leadership in the Australasian Virology Society. She mentors students and collaborates with clinical and commercial partners to translate her findings into novel therapies. Her lab is engaged in multiple funded projects focused on silicosis, influenza immunopathology, and host-directed antiviral strategies, reflecting her commitment to impactful, interdisciplinary research.
